Metabolic Response of Glioblastoma to Superselective Intra-Arterial Cerebral Infusion of Bevacizumab: A Proton MR Spectroscopic Imaging Study

References

1. 1.↵
   1. Stupp R

   . Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459– 66

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Abraham J

   . Bevacizumab in recurrent glioblastoma. Commun Oncol 2009; 6: 397– 400

   CrossRef
3. 3.↵
   1. Cohen MH,
   2. Shen YL,
   3. Keegan P,
   4. et al

   . FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14: 1131– 38

   Abstract/FREE Full Text
4. 4.↵
   1. Mukherji SK

   . Bevacizumab (Avastin). AJNR Am J Neuroradiol 2010; 31: 235– 36

   Abstract/FREE Full Text
5. 5.↵
   1. Boockvar JA,
   2. Tsiouris AJ,
   3. Hofstetter CP,
   4. et al

   . Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. J Neurosurg 2011; 114: 624– 32

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Riina HA,
   2. Fraser JF,
   3. Fralin S,
   4. et al

   . Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol 2009; 8: 145– 50

   PubMed
7. 7.↵
   1. Burkhardt J-K,
   2. Riina HA,
   3. Shin BJ,
   4. et al

   . Intra-arterial delivery of bevacizumab after blood brain barrier disruption for the treatment of recurrent glioblastoma: progression free survival and overall survival. World Neurosurg 2012; 77: 130– 34

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Fischer I,
   2. Cunliffe CH,
   3. Bollo RJ,
   4. et al

   . High-grade glioma before and after treatment with radiation and Avastin: initial observations. J Neurooncol 2008; 10: 700– 08
9. 9.↵
   1. Pope WB,
   2. Lai A,
   3. Nghiemphu P,
   4. et al

   . MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66: 1258– 60

   Abstract/FREE Full Text
10. 10.↵
    1. Wagle N,
    2. Nghiemphu L,
    3. Lai A,
    4. et al

    . Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab. Pharmacogenomics Pers Med 2010; 3: 79– 85
11. 11.↵
    1. de Groot JF,
    2. Yung WKA

    . Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008; 14: 279– 85

    PubMed
12. 12.↵
    1. Balmaceda C,
    2. Critchell D,
    3. Mao X,
    4. et al

    . Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol 2006; 76: 185– 91

    CrossRefPubMed
13. 13.↵
    1. Smith EA,
    2. Carlos RC,
    3. Junck LR,
    4. et al

    . Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009; 192: W45– 52

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Weybright P,
    2. Sundgren PC,
    3. Maly P,
    4. et al

    . Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005; 185: 1471– 76

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Srinivasan R,
    2. Phillips JJ,
    3. VandenBerg SR,
    4. et al

    . Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neurooncol 2010; 12: 1152– 61

    Abstract/FREE Full Text
16. 16.↵
    1. Fan G

    . Comments and controversites: magnetic resonance spectroscopy and gliomas. Cancer Imaging 2006; 6: 113– 15

    CrossRefPubMed
17. 17.↵
    1. Wen PY,
    2. MacDonald DR,
    3. Reardon DA,
    4. et al

    . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J ClinOncol 28: 1963–72
18. 18.↵
    1. Duyn JH,
    2. Gillen J,
    3. Sobering G,
    4. et al

    . Multisection proton MR spectroscopic imaging of the brain. Radiology 1993; 188: 277– 82

    PubMedWeb of Science
19. 19.↵
    1. Al-Okaili RN,
    2. Krejza J,
    3. Wang S,
    4. et al

    . Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 2006; 26: S173– 89

    CrossRefPubMed
20. 20.↵
    1. Lin A,
    2. Bluml S,
    3. Mamelak AN

    . Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neurooncol 1999; 45: 69– 81

    CrossRefPubMed
21. 21.↵
    1. Lin A,
    2. Ross BD,
    3. Harris K,
    4. et al

    . Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005; 2: 197– 214

    Abstract/FREE Full Text
22. 22.↵
    1. McKnight TR,
    2. con dem Bussche MH,
    3. Vigneron DB,
    4. et al

    . Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97: 794– 802

    PubMedWeb of Science
23. 23.↵
    1. Hygino da Cruz LC Jr.,
    2. Rodriguez I,
    3. Domingues RC,
    4. et al

    . Pseudoprogression and pseudoreponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011; 32: 1978– 85

    Abstract/FREE Full Text
24. 24.↵
    1. Khasraw M,
    2. Lassman AB

    . Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010; 12: 26– 33

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Macdonald DR,
    2. Cascino TL,
    3. Schold SC Jr.,
    4. et al

    . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277– 80

    Abstract
26. 26.↵
    1. Friedman HS,
    2. Prados MD,
    3. Wen PY,
    4. et al

    . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 227: 4733– 40
27. 27.↵
    1. Dhermain FG,
    2. Hau P,
    3. Lanferman H,
    4. et al

    . Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010; 9: 906– 20

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Gerstner ER,
    2. Sorensen AG,
    3. Jain RK,
    4. et al

    . Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 2008; 21: 728– 35

    CrossRefPubMed